Page 8 - நிர்வகிக்கவும் செலவு அமைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நிர்வகிக்கவும் செலவு அமைப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நிர்வகிக்கவும் செலவு அமைப்பு Today - Breaking & Trending Today

Covid 19 coronavirus: Government's vaccination register 'just putting money into a Silicon Valley billionaire's pocket'


Covid 19 coronavirus: Government s vaccination register just putting money into a Silicon Valley billionaire s pocket
12 Apr, 2021 05:32 AM
5 minutes to read
Prime Minister Jacinda Ardern addresses media at opening of telehealth service in Auckland.
The Ministry of Health s $38 million effort to create an online system to manage Covid-19 vaccinations is just putting money into a Silicon Valley billionaire s pocket , local IT industry group NZRise says.
Previous criticism has
centred on a security breach involving the data of more than 700 patients; the Government s inability - until this week - to provide accurate vaccination data; and the related issue of DHBs striking out on their own path, using different software systems, while they wait for the Government s new cloud-based solution to be fleshed out. ....

New Zealand , Larry Ellison , Don Christie , Marc Benioff , Ministry Of Health , Silicon Valley , Victoria Maclennan , Valentia Technologies , Procurement Rules , Crush Digital , New Zealand Based , Co Vid , Corona Virus , Mo Ney , Covid 19 , புதியது ஜீலாந்து , லாரி எலிசன் , தாதா கிறிஸ்டி , மார்க் பெனியோஃப் , அமைச்சகம் ஆஃப் ஆரோக்கியம் , சிலிக்கான் பள்ளத்தாக்கு , ப்ரொக்யூர்மெஂட் விதிகள் , அவசரம் டிஜிட்டல் , புதியது ஜீலாந்து அடிப்படையிலானது , இணை வித் , கொரோனா வைரஸ் ,

Moleculin Biotech Engages IQVIA To Manage Potential COVID-19 Clinical Trial


Moleculin Biotech Engages IQVIA To Manage Potential COVID-19 Clinical Trial
SOUTH SAN FRANCISCO (dpa-AFX) - Moleculin Biotech Inc. (MBRX) said that it has engaged IQVIA Biotech, a contract research organization, to manage the company s effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.
WP1122 is a prodrug of 2-DG, a well-known antimetabolite with the ability to inhibit glycolysis and alter glycosylation, two processes critical to coronaviruses like SARS-CoV-2, the virus responsible for COVID-19.
The company noted that 2-DG has shown activity against SARS-CoV-2, other coronaviruses and other non-coronaviruses. But the company believes its therapeutic potential is limited by its inherent lack of drug-like properties. ....

Moleculin Biotech Inc , Co Vid , இணை வித் ,